Merck's cancer drug KEYTRUDA (pembrolizumab), combined with Padcev (enfortumab vedotin-ejfv), has received a positive recommendation from the European Medicines Agency's…
Read More

Merck's cancer drug KEYTRUDA (pembrolizumab), combined with Padcev (enfortumab vedotin-ejfv), has received a positive recommendation from the European Medicines Agency's…
Read More
Professor Rik Bryan, Professor of Urothelial Cancer Research and Director of the Bladder Cancer Research Centre at the University of…
Read More